List of patient-reported quality of life surveys: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
Line 19: Line 19:
# The [[SF-36|Short Form 36 (SF-36) Health Survey]] is a survey of general health developed by the [[RAND corporation]].<ref>{{cite web|title=36-Item Short Form Survey from the RAND Medical Outcomes Study|url=http://www.rand.org/health/surveys_tools/mos/mos_core_36item.html|work=RAND.org|publisher=RAND|accessdate=20 November 2013}}</ref> It was designed for use in clinical practice, research, health policy evaluations and population surveys.<ref>{{cite journal|last=Ware|first=John E.|coauthors=Sherbourne, Cathy Donald|title=The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection.|journal=Medical Care|year=1992|month=June|volume=30|issue=6|pages=473–483|url=http://ovidsp.tx.ovid.com/sp-3.10.0b/ovidweb.cgi?T=JS&PAGE=fulltext&D=ovft&AN=00005650-199206000-00002&NEWS=N&CSC=Y&CHANNEL=PubMed|accessdate=20 November 2013}}</ref> It has been used in numerous studies including ones investigating [[giardia intestinalis]],<ref>{{cite journal|last=Abulhasan|first=Mohamad|coauthors=Elshazly, Tarek A.; Eida, Mohamad; Albadry, Ayman|title=Giardia intestinalis in patients with nonulcer dyspepsia.|journal=Arab Journal of Gastroenterology|year=2013|month=September|volume=14|issue=3|pages=126–129|doi=10.1016/j.ajg.2013.08.004|url=http://www.arabgastro.com/article/S1687-1979(13)00121-4/abstract|accessdate=20 November 2013}}</ref> [[breast cancer]] survivors<ref>{{cite journal|last=Cuevas|first=B.T.|coauthors=Hughes, D.C.; Parma, D.L.; Trevino-Whitaker, R.A.; Ghosh, S.; Li, R.; Ramirez, A.G.|title=Motivation, exercise, and stress in breast cancer survivors.|journal=Supportive Care in cancer|year=2013|month=November|url=http://www.ncbi.nlm.nih.gov/pubmed/24249424|accessdate=20 November 2013}}</ref> and [[Parkinson’s disease]].<ref>{{cite journal|last=Avidan|first=A|coauthors=Hays, R.D.; Diaz, N.; Bordelon, Y.; Thompson, A.W.; Vassar, S.D.; Vickrey, B.G.|title=Associations of sleep disturbance symptoms with health-related quality of life in Parkinson's disease.|journal=The Journal of Neuropsychiatry and Clinical Neurosciences|year=2013|month=October|volume=25|issue=4|pages=319–326|doi=10.1176/appi.neuropsych.12070175.|url=http://www.ncbi.nlm.nih.gov/pubmed/24247858|accessdate=20 November 2013}}</ref>.
# The [[SF-36|Short Form 36 (SF-36) Health Survey]] is a survey of general health developed by the [[RAND corporation]].<ref>{{cite web|title=36-Item Short Form Survey from the RAND Medical Outcomes Study|url=http://www.rand.org/health/surveys_tools/mos/mos_core_36item.html|work=RAND.org|publisher=RAND|accessdate=20 November 2013}}</ref> It was designed for use in clinical practice, research, health policy evaluations and population surveys.<ref>{{cite journal|last=Ware|first=John E.|coauthors=Sherbourne, Cathy Donald|title=The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection.|journal=Medical Care|year=1992|month=June|volume=30|issue=6|pages=473–483|url=http://ovidsp.tx.ovid.com/sp-3.10.0b/ovidweb.cgi?T=JS&PAGE=fulltext&D=ovft&AN=00005650-199206000-00002&NEWS=N&CSC=Y&CHANNEL=PubMed|accessdate=20 November 2013}}</ref> It has been used in numerous studies including ones investigating [[giardia intestinalis]],<ref>{{cite journal|last=Abulhasan|first=Mohamad|coauthors=Elshazly, Tarek A.; Eida, Mohamad; Albadry, Ayman|title=Giardia intestinalis in patients with nonulcer dyspepsia.|journal=Arab Journal of Gastroenterology|year=2013|month=September|volume=14|issue=3|pages=126–129|doi=10.1016/j.ajg.2013.08.004|url=http://www.arabgastro.com/article/S1687-1979(13)00121-4/abstract|accessdate=20 November 2013}}</ref> [[breast cancer]] survivors<ref>{{cite journal|last=Cuevas|first=B.T.|coauthors=Hughes, D.C.; Parma, D.L.; Trevino-Whitaker, R.A.; Ghosh, S.; Li, R.; Ramirez, A.G.|title=Motivation, exercise, and stress in breast cancer survivors.|journal=Supportive Care in cancer|year=2013|month=November|url=http://www.ncbi.nlm.nih.gov/pubmed/24249424|accessdate=20 November 2013}}</ref> and [[Parkinson’s disease]].<ref>{{cite journal|last=Avidan|first=A|coauthors=Hays, R.D.; Diaz, N.; Bordelon, Y.; Thompson, A.W.; Vassar, S.D.; Vickrey, B.G.|title=Associations of sleep disturbance symptoms with health-related quality of life in Parkinson's disease.|journal=The Journal of Neuropsychiatry and Clinical Neurosciences|year=2013|month=October|volume=25|issue=4|pages=319–326|doi=10.1176/appi.neuropsych.12070175.|url=http://www.ncbi.nlm.nih.gov/pubmed/24247858|accessdate=20 November 2013}}</ref>.
# The Sickness Impact Profile (SIP) was developed in 1997 by the [[John Hopkins University]]<ref>{{cite journal|last=Gilson|first=B.S.|coauthors=Gilson, J.S.; Bergner, M.; Bobbit, R.A.; Kressel, S.; Pollard, W.E.; Vesselago, M.|title=The sickness impact profile. Development of an outcome measure of health care.|journal=American Journal of Public Health|year=1975|month=December|volume=65|issue=12|pages=1304-1310|url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1776251/|accessdate=22 November 2013}}</ref>. It consists of 136 items and has been adapted for strokes<ref>{{cite journal|last=van Straten|first=A.|coauthors=de Haan, R.J.; Limburg, M.; Schuling, J.; Bossuyt, P.M.; van den Bos, G.A.M.|title=A Stroke-Adapted 30-Item Version of the Sickness Impact Profile to Assess Quality of Life (SA-SIP30)|journal=Stroke|year=1997|volume=28|pages=2155-2161|doi=10.1161/​01.STR.28.11.2155|url=http://stroke.ahajournals.org/content/28/11/2155.long|accessdate=22 November 2013}}</ref>, patients with ileal urinary diversions<ref>{{cite journal|last=Prcic|first=Alden|coauthors=Aganovic, Damir; Hadziosmanovic, Osman|title=Sickness Impact Profile (SIP) Score, a Good Alternative Instrument for Measuring Quality of Life in Patients with Ileal Urinary Diversions|journal=Acta Informatica Medica|year=2013|volume=21|issue=3|pages=160-165|doi=10.5455/aim.2013.21.160-165|url=http://www.scopemed.org/?mno=42548|accessdate=22 November 2013}}</ref> and ex-ICU patients<ref>{{cite journal|last=Hulsebos|first=R.G.|coauthors=Beltman, F.W.; dos Reis Miranda, D.; Spangenberg, J.F.A.|title=Measuring quality of life with the sickness impact profile: A pilot study|journal=Intensive Care Medicine|year=1991|volume=17|issue=5|pages=285-288|doi=10.1007/BF01713939|url=http://link.springer.com/article/10.1007%2FBF01713939|accessdate=22 November 2013}}</ref>.
# The Sickness Impact Profile (SIP) was developed in 1997 by the [[John Hopkins University]]<ref>{{cite journal|last=Gilson|first=B.S.|coauthors=Gilson, J.S.; Bergner, M.; Bobbit, R.A.; Kressel, S.; Pollard, W.E.; Vesselago, M.|title=The sickness impact profile. Development of an outcome measure of health care.|journal=American Journal of Public Health|year=1975|month=December|volume=65|issue=12|pages=1304-1310|url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1776251/|accessdate=22 November 2013}}</ref>. It consists of 136 items and has been adapted for strokes<ref>{{cite journal|last=van Straten|first=A.|coauthors=de Haan, R.J.; Limburg, M.; Schuling, J.; Bossuyt, P.M.; van den Bos, G.A.M.|title=A Stroke-Adapted 30-Item Version of the Sickness Impact Profile to Assess Quality of Life (SA-SIP30)|journal=Stroke|year=1997|volume=28|pages=2155-2161|doi=10.1161/​01.STR.28.11.2155|url=http://stroke.ahajournals.org/content/28/11/2155.long|accessdate=22 November 2013}}</ref>, patients with ileal urinary diversions<ref>{{cite journal|last=Prcic|first=Alden|coauthors=Aganovic, Damir; Hadziosmanovic, Osman|title=Sickness Impact Profile (SIP) Score, a Good Alternative Instrument for Measuring Quality of Life in Patients with Ileal Urinary Diversions|journal=Acta Informatica Medica|year=2013|volume=21|issue=3|pages=160-165|doi=10.5455/aim.2013.21.160-165|url=http://www.scopemed.org/?mno=42548|accessdate=22 November 2013}}</ref> and ex-ICU patients<ref>{{cite journal|last=Hulsebos|first=R.G.|coauthors=Beltman, F.W.; dos Reis Miranda, D.; Spangenberg, J.F.A.|title=Measuring quality of life with the sickness impact profile: A pilot study|journal=Intensive Care Medicine|year=1991|volume=17|issue=5|pages=285-288|doi=10.1007/BF01713939|url=http://link.springer.com/article/10.1007%2FBF01713939|accessdate=22 November 2013}}</ref>.
# The Health Utilities Index measures health status, health-related quality of life and produces utility scores<ref>{{cite journal|last=Horsman|first=John|coauthors=Furlong, William; Feeny, David; Torrance, George|title=The Health Utilities Index (HUI®): concepts, measurement properties and applications|journal=Health And Quality Of Life Outcomes|year=2003|volume=1|issue=54|doi=10.1186/1477-7525-1-54|url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC293474/|accessdate=22 November 2013}}</ref>. It was developed by Health Utilities Inc. in Canada<ref>{{cite journal|last=Furlong|first=W.J.|coauthors=Feeny, D.H.; Torrance, G.W.; Barr, R.D.|title=The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies.|journal=Annals of medicine|year=2001|month=July|volume=33|issue=5|pages=375-384|url=http://www.ncbi.nlm.nih.gov/pubmed/11491197|accessdate=22 November 2013}}</ref>. It has been used in clinical studies investigating knee osteoarthritis<ref>{{cite journal|last=Davis|first=Erin M.|coauthors=Lynd, Larry D.; Grubisic, Maja; Kopec, Jacek A.; Sayre, Eric C.; Cibere, Jolanda; Esdaile, John; Marra, Carlo A.|title=Responsiveness of Health State Utility Values in Knee Osteoarthritis|journal=The Journal of Rheumatology|year=2013|volume=40|issue=11|doi=10.3899/jrheum.130176|url=http://www.jrheum.org/content/early/2013/10/29/jrheum.130176.long|accessdate=22 November 2013}}</ref>, urinary incontinence<ref>{{cite journal|last=Harvie|first=Heidi S.|coauthors=Shea, Judy A.; Andy, Uduak U.; Propert, Kate; Schwart, J. Sanford; Arya, Lily A.|title=Validity of utility measures for women with urge, stress, and mixed urinary incontinence.|journal=American Journal of Obstetrics and Gynecology|year=2013|doi=10.1016/j.ajog.2013.09.025|url=http://www.sciencedirect.com/science/article/pii/S0002937813009794|accessdate=22 November 2013}}</ref> and children who have been admitted to intensive care<ref>{{cite journal|last=Ebrahim|first=Shanil|coauthors=Parshuram, Christopher|title=Comparison of utility scores from the Visual Analog Scale and Health Utilities Index 3 in children following pediatric intensive care unit admission|journal=Journal of Child Health Care|year=2013|doi=10.1177/1367493513496909|url=http://chc.sagepub.com/content/early/2013/08/02/1367493513496909.full.pdf+html|accessdate=22 November 2013}}</ref>.
* '''[[Fatigue (medical)|Fatigue]].''' The Unidimensional Fatigue Impact Scale (U-FIS) was developed in 2009 by Galen Research primarily for the measurement of multiple sclerosis related fatigue.<ref>{{cite journal|last=Meads|first=D.M.|coauthors=Doward, L.C.; McKenna, S.P.; Fisk, J.; Twiss, J.; Eckert, B.|title=The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS)|journal=Multiple Sclerosis|year=2009|volume=15|issue=10|pages=1228–1238|doi=10.1177/1352458509106714}}</ref> It has been recommended for use in determining fatigue by an independent clinical research study<ref>{{cite journal|last=Elbers|first=Roy G.|coauthors=Rietberg, Marc B.; van Wegen, Erwin E.H.; Verhoef, John; Kramer, Sharon F.; Terwee, Caroline B, Kwakkel, Gert|title=Self-report fatigue questionnaires in multiple sclerosis, Parkinson’s disease and stroke: a systematic review of measurement properties|journal=Quality of Life Research|year=2012|month=August|volume=21|issue=6|pages=925–944|doi=10.1007/s11136-011-0009-2|url=http://link.springer.com/article/10.1007%2Fs11136-011-0009-2|accessdate=20 November 2013}}</ref> and translated into eight languages.<ref>{{cite web|title=Measures Database|url=http://www.galen-research.com/measures-database/|work=Galen-Research.com|publisher=Galen Research|accessdate=20 November 2013}}</ref>
* '''[[Fatigue (medical)|Fatigue]].''' The Unidimensional Fatigue Impact Scale (U-FIS) was developed in 2009 by Galen Research primarily for the measurement of multiple sclerosis related fatigue.<ref>{{cite journal|last=Meads|first=D.M.|coauthors=Doward, L.C.; McKenna, S.P.; Fisk, J.; Twiss, J.; Eckert, B.|title=The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS)|journal=Multiple Sclerosis|year=2009|volume=15|issue=10|pages=1228–1238|doi=10.1177/1352458509106714}}</ref> It has been recommended for use in determining fatigue by an independent clinical research study<ref>{{cite journal|last=Elbers|first=Roy G.|coauthors=Rietberg, Marc B.; van Wegen, Erwin E.H.; Verhoef, John; Kramer, Sharon F.; Terwee, Caroline B, Kwakkel, Gert|title=Self-report fatigue questionnaires in multiple sclerosis, Parkinson’s disease and stroke: a systematic review of measurement properties|journal=Quality of Life Research|year=2012|month=August|volume=21|issue=6|pages=925–944|doi=10.1007/s11136-011-0009-2|url=http://link.springer.com/article/10.1007%2Fs11136-011-0009-2|accessdate=20 November 2013}}</ref> and translated into eight languages.<ref>{{cite web|title=Measures Database|url=http://www.galen-research.com/measures-database/|work=Galen-Research.com|publisher=Galen Research|accessdate=20 November 2013}}</ref>
* '''[[Genital Herpes]].'''
* '''[[Genital Herpes]].'''

Revision as of 15:55, 22 November 2013

This page lists patient-reported quality of life surveys used in the field of medicine, pharmaceuticals, and other scientific trials. These surveys are patient-reported outcome measures, may be questionnaires or surveys, and may be used to evaluate patient satisfaction, symptoms, disease state, or psychological well-being.

List

  1. The Parents’ Index of Quality of Life in Atopic Dermatitis (PiQOL-AD) measures the impact that atopic dermatitis (AD) has on quality of life, from the parents’ perspective.[13] It has 28 items and was developed simultaneously in the United Kingdom, The Netherlands, Germany, Italy, Spain, France and the United States.[14] It has been utilised in several research studies investigating the treatment of paediatric atopic dermatitis with pimecrolimus.[15][16][17] and also in a research study regarding health-related quality of life measurement in children in Ibero-American countries.[18]
  2. The Quality of Life Index for Atopic Dermatitis (QoLIAD) measures the impact that atopic dermatitis (AD) has on a given patient’s quality of life.[19] It is a 25 item questionnaire for patients over the age of 16.[20] The QoLIAD has also been utilized in studies looking into educational intervention,[21][22] topical corticosteroids[23] and pimecrolimus.[24]
  1. The EuroQoL (EQ-5D) is a generalised health-related quality of life measure which was developed in 1991 by the EuroQol Group.[39] It has five standard dimensions and has been translated into over 60 languages.[40] The EuroQoL has been extensively used in clinical trials, investigating a range of topics including overactive bladder,[41] attention deficit hyperactivity disorder[42] and denosumab for osteoporosis.[43]
  2. The Nottingham Health Profile (NHP) is a general patient reported outcome designed to measure a patient’s view of their own health status, in a number of areas.[44] It can be completed in 5 minutes.[45] It was developed in 1975 and current copyright belongs to Galen Research.[46] Clinical research studies where the NHP has been utilized include investigations into erythropoiesis-stimulating agents,[47] glucocorticoid replacement therapy[48] and transcutaneous electrical nerve stimulation for tinnitus.[49]
  3. The Short Form 36 (SF-36) Health Survey is a survey of general health developed by the RAND corporation.[50] It was designed for use in clinical practice, research, health policy evaluations and population surveys.[51] It has been used in numerous studies including ones investigating giardia intestinalis,[52] breast cancer survivors[53] and Parkinson’s disease.[54].
  4. The Sickness Impact Profile (SIP) was developed in 1997 by the John Hopkins University[55]. It consists of 136 items and has been adapted for strokes[56], patients with ileal urinary diversions[57] and ex-ICU patients[58].
  5. The Health Utilities Index measures health status, health-related quality of life and produces utility scores[59]. It was developed by Health Utilities Inc. in Canada[60]. It has been used in clinical studies investigating knee osteoarthritis[61], urinary incontinence[62] and children who have been admitted to intensive care[63].
  • Fatigue. The Unidimensional Fatigue Impact Scale (U-FIS) was developed in 2009 by Galen Research primarily for the measurement of multiple sclerosis related fatigue.[64] It has been recommended for use in determining fatigue by an independent clinical research study[65] and translated into eight languages.[66]
  • Genital Herpes.
  1. The Herpes Outbreak Impact Questionnaire (HOIQ) is a quality of life measure designed to determine the impact of recurrent genital herpes outbreaks on a patient’s life.[67] Its efficacy has been tested in an Australian clinical trial.[68]
  2. The Herpes Symptom Checklist (HSC) was developed alongside the HOIQ in order to assess daily symptoms of genital herpes outbreaks.[69] It was also used in an Australian clinical trial which tested the effectiveness of famciclovir.[70]
  3. The Recurrent Genital Herpes Quality of Life (RGHQoL) measure was developed in 1998 by Galen Research in order to assess the impact recurrent genital herpes has on quality of life.[71] It has been used in clinical trials investigating famciclovir,[72] suppressive antiviral therapy[73] and patient perspectives and quality of life.[74][75]

References

  1. ^ "ACQLI" (PDF). Galen-Research.com. Galen Research. Retrieved 11 November 2013.
  2. ^ "Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 11 November 2013.
  3. ^ "Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-2)". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 11 November 2013.
  4. ^ "Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 11 November 2013.
  5. ^ Levy, Karen (2012). "Does Pharmacological Treatment of Neuropsychiatric Symptoms in Alzheimer's Disease Relieve Caregiver Burden?". Drugs and Aging. 29 (3): 167–179. doi:10.2165/11599140-000000000-00000. Retrieved 11 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  6. ^ Doward, L.C. (2003). "Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis". Annals of the Rheumatic Diseases. 62 (1): 20–26. doi:10.1136/ard.62.1.20. PMC 1754293. PMID 12480664. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  7. ^ van der Heijde, Desiree M. (17/08/2009). "Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis". Arthritis Research & Therapy. 11 (4): 1–12. doi:10.1186/ar2790. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
  8. ^ Davis Jr., John C. (15/08/2007). "Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study". Arthritis Care & Research. 57 (6): 1050–1057. doi:10.1002/art.22887. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  9. ^ Marzo-Ortega, Helena (2001-09-26). "Efficacy of Etanercept in the Treatment of the Entheseal Pathology in Resistant Spondylarthropathy". Arthritis & Rheumatism. 44 (9): 2112–2117. doi:10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  10. ^ Marzo-Ortega, H (2003). "Bone mineral density improvement in spondyloarthropathy after treatment with etanercept". Annals of Rheumatic Diseases. 62: 1020–1021. doi:10.1136/ard.62.10.1020. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  11. ^ Meads, David M. (05/2010). "Development and validation of the Asthma Life Impact Scale (ALIS)". Respiratory Medicine. 104 (5): 633–643. doi:10.1016/j.rmed.2009.11.023. PMID 20053543. Retrieved 14 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  12. ^ Crawford, SR. "Further Developments of the Asthma Life Impact Scale (ALIS)" (PDF). Galen-Research.com. Galen Research. Retrieved 14 October 2013.
  13. ^ Arnold, RJG (2005). "PSK8 IMPACT OF ATOPIC DERMATITIS ON THE QUALITY-OF-LIFE OF PARENTS OF CHILDREN WITH ATOPIC DERMATITIS". Value in Health. 8 (3): 332. doi:10.1016/S1098-3015(10)62872-0. Retrieved 25 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  14. ^ McKenna, Stephen P. (2005). "International development of the Parents' Index of Quality of Life in Atopic Dermatitis (PIQoL-AD)". Quality of Life Research. 14 (1): 231–241. doi:10.1007/s11136-004-4231-z. PMID 15789957. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  15. ^ McKenna, S.P. (2006). "Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel®, SDZ ASM 981): impact on quality of life and health-related quality of life". Journal of the European Academy of Dermatology and Venereology. 20 (3): 248–254. doi:10.1111/j.1468-3083.2006.01383.x. PMID 16503881. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  16. ^ Wahn, Ulrich (2002). "Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children". Pediatrics. 110 (1): e2. doi:10.1542/peds.110.1.e2. PMID 12093983. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  17. ^ Kapp, Alexander (2002). "Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug". Journal of Allergy and Clinical Immunology. 110 (2): 227–284. doi:10.1067/mai.2002.126500. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  18. ^ Rajmil, Luis (2012-03-01). "Health-Related Quality of Life Measurement in Children and Adolescents in Ibero-American Countries, 2000 to 2010". Value in Health. 15 (2): 312–322. doi:10.1016/j.jval.2011.11.028. PMID 22433763. Retrieved 25 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  19. ^ Meads, D.M. (2005). "PSK6 INTERPRETING SCORES ON THE QUALITY OF LIFE INDEX FOR ATOPIC DERMATITIS (QOLIAD)". Value in Health. 8 (3): 331–332. doi:10.1016/S1098-3015(10)62870-7. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  20. ^ Ehlken, B. (2003). "PSN12 QUALITY-OF-LIFE IN PATIENTS SUFFERING FROM ATOPIC DERMATITIS IN GERMANY". Value in Health. 6 (6): 787–788. doi:10.1016/S1098-3015(10)62005-0. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  21. ^ Lambert, J. (2011). "A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results". Archives of Dermatological Research. 303 (1): 57–63. doi:10.1007/s00403-010-1082-z. PMID 20842368. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  22. ^ Bostoen, J. (2012). "An educational programme for patients with psoriasis and atopic dermatitis: a prospective randomized controlled trial". The British Journal of Dermatology. 167 (5): 1025–1031. doi:10.1111/j.1365-2133.2012.11113.x. PMID 22709422. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  23. ^ Moed, Heleen (2012). Moed, Heleen (ed.). "Different strategies for using topical corticosteroids for established eczema". Cochrane Database of Systematic Reviews (10). doi:10.1002/14651858.CD010080. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  24. ^ Lecomte, P. (2006). "PSK6 BELGIAN DRUG UTILISATION STUDY OF ELIDEL® IN ROUTINE PRACTICE IN ATOPIC DERMATITIS". Value in Health. 9 (6): A268. doi:10.1016/S1098-3015(10)63408-0. Retrieved 28 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  25. ^ Dawson, J (1998). "Questionnaire on the perceptions of patients about total knee replacement". Journal of Bone and Joint Surgery. 80: 63–69. PMID 9460955. {{cite journal}}: |access-date= requires |url= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  26. ^ Xie F, Ye H, Zhang Y, Liu X, Lei T, Li S (November 2010). "Extension from inpatients to outpatients: validity and reliability of the Oxford Knee Score in measuring health outcomes in patients with knee osteoarthritis." International Journal of Rheumatic Diseases. doi:10.1111/j.1756-185X.2010.01580.x [1]
  27. ^ McKenna, S.P. (1994). "A measure of family disruption for use in chickenpox and other childhood illnesses". Social Science and Medicine. 38 (5): 725–731. Retrieved 13 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  28. ^ Mast, T. Christopher (2009). "The impact of rotavirus gastroenteritis on the family". BMC Pediatrics. 9 (11): 1–9. doi:10.1186/1471-2431-9-11. Retrieved 13 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
  29. ^ Weldam, Saskia W.M. (05/2013). "Evaluation of Quality of Life instruments for use in COPD care and research: A systematic review". International Journal of Nursing Studies. 50 (5): 688–707. doi:10.1016/j.ijnurstu.2012.07.017. PMID 22921317. Retrieved 11 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  30. ^ "Measures Database". Galen-Research.com. Galen Research. Retrieved 11 October 2013.
  31. ^ Lopez-Campos, Jose Luis (2009). "Importance of fatigue, sleep quality and mood in patients with chronic obstructive pulmonary disease and the need for measurement instruments". Archivos de Bronconeumologia. 45 (5): 2–6. doi:10.1016/S0300-2896(09)72948-5. Retrieved 14 October 2013.
  32. ^ Amir, Marianne (2002). "Psychometric Properties of the SF-12 (Hebrew Version) in a Primary Care Population in Israel". Medical Care. 40 (10): 918–928. doi:10.1097/00005650-200210000-00009. PMID 12395025. Retrieved 21 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  33. ^ McKenna, Stephen P. (1992). "A new measure of quality of life in depression: Testing the reliability and construct validity of the QLDS". Health Policy. 22 (3): 321–330. Retrieved 22 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  34. ^ Baca Baldomero, E (2003). "Quality of life, in depressed patients in Primary Health Care setting. Effectiveness and safety of venlafaxine extended release". Actas españolas de psiquiatría. 31 (6): 331–338. Retrieved 22 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  35. ^ Detke, Michael J. (2002). "Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression". Journal of Psychiatric Research. 36 (6): 383–390. Retrieved 22 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  36. ^ Hudson, James I. (2007). "Duloxetine in the treatment of major depressive disorder: an open-label study". BMC Psychiatry. 7 (43). doi:10.1186/1471-244X-7-43. Retrieved 22 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
  37. ^ Kornstein, Susan G. (2006). "Duloxetine Efficacy for Major Depressive Disorder in Male vs. Female Patients: Data From 7 Randomized, Double-Blind, Placebo-Controlled Trials". Journal of Clinical Psychiatry. 67: 761–770. Retrieved 22 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  38. ^ Dunner, David L. (2001). "Improved Health-Related Quality of Life and Reduced Productivity Loss After Treatment With Bupropion Sustained Release: A Study in Patients With Major Depression". Primary Care Companion to The Journal of Clinical Psychiatry. 3 (1): 10–16. Retrieved 22 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  39. ^ Brooks, Richard (1996). "EuroQol: the current state of play". Health Policy. 37 (1): 53–72. doi:10.1016/0168-8510(96)00822-6. Retrieved 20 November 2013. {{cite journal}}: Unknown parameter |month= ignored (help)
  40. ^ "Euroqol EQ-5D (EQ-5D)". PROQOLID.org. Mapi Research Trust. Retrieved 20 November 2013.
  41. ^ Desroziers, K (2013). "Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder". Health And Quality Of Life Outcomes. 11 (1): 200. Retrieved 20 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  42. ^ Bouwmans, Clazien (2013). "Validity and responsiveness of the EQ-5D and the KIDSCREEN-10 in children with ADHD". The European Journal of Health Economics. doi:10.1007/s10198-013-0540-x. Retrieved 20 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  43. ^ Parthan, A. (2013). "Denosumab: A cost-effective alternative for older men with osteoporosis from a Swedish payer perspective". Bone: 1–9. doi:10.1016/j.bone.2013.11.002. Retrieved 20 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  44. ^ Hunt, Sonja M.; McKenna, S.P.; McEwen, J.; Williams, Jan; Papp, Evelyn (1981). "The Nottingham health profile: Subjective health status and medical consultations". Social Science & Medicine. Part A: Medical Psychology & Medical Sociology. 15 (3): 221–9. doi:10.1016/0271-7123(81)90005-5. PMID 6973203.
  45. ^ Ebrahim, Shah; Barer, David; Nouri, Fiona (1986). "Use of the Nottingham Health Profile with patients after a stroke". Journal of Epidemiology & Community Health. 40 (2): 166–9. doi:10.1136/jech.40.2.166. JSTOR 25566637. PMC 1052513. PMID 3746178.
  46. ^ Hunt, SM; McEwen, J; McKenna, SP (1985). "Measuring health status: A new tool for clinicians and epidemiologists". The Journal of the Royal College of General Practitioners. 35 (273): 185–8. PMC 1960139. PMID 3989783.
  47. ^ Johansen, K. L.; Finkelstein, F. O.; Revicki, D. A.; Evans, C.; Wan, S.; Gitlin, M.; Agodoa, I. L. (2011). "Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients". Nephrology Dialysis Transplantation. 27 (6): 2418–25. doi:10.1093/ndt/gfr697. PMID 22187314.
  48. ^ Behan, Lucy-Ann; Rogers, Bairbre; Hannon, Mark J.; O'Kelly, Patrick; Tormey, William; Smith, Diarmuid; Thompson, Christopher J.; Agha, Amar (2011). "Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients". Clinical Endocrinology. 75 (4): 505–13. doi:10.1111/j.1365-2265.2011.04074.x. PMID 21521342.
  49. ^ Aydemir, G; Tezer, M S; Borman, P; Bodur, H; Unal, A (2006). "Treatment of tinnitus with transcutaneous electrical nerve stimulation improves patients' quality of life". The Journal of Laryngology & Otology. 120 (6): 442–5. doi:10.1017/S0022215106000910. PMID 16556347.
  50. ^ "36-Item Short Form Survey from the RAND Medical Outcomes Study". RAND.org. RAND. Retrieved 20 November 2013.
  51. ^ Ware, John E. (1992). "The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection". Medical Care. 30 (6): 473–483. Retrieved 20 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  52. ^ Abulhasan, Mohamad (2013). "Giardia intestinalis in patients with nonulcer dyspepsia". Arab Journal of Gastroenterology. 14 (3): 126–129. doi:10.1016/j.ajg.2013.08.004. Retrieved 20 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  53. ^ Cuevas, B.T. (2013). "Motivation, exercise, and stress in breast cancer survivors". Supportive Care in cancer. Retrieved 20 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  54. ^ Avidan, A (2013). "Associations of sleep disturbance symptoms with health-related quality of life in Parkinson's disease". The Journal of Neuropsychiatry and Clinical Neurosciences. 25 (4): 319–326. doi:10.1176/appi.neuropsych.12070175. Retrieved 20 November 2013. {{cite journal}}: Check |doi= value (help); Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  55. ^ Gilson, B.S. (1975). "The sickness impact profile. Development of an outcome measure of health care". American Journal of Public Health. 65 (12): 1304–1310. Retrieved 22 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  56. ^ van Straten, A. (1997). "A Stroke-Adapted 30-Item Version of the Sickness Impact Profile to Assess Quality of Life (SA-SIP30)". Stroke. 28: 2155–2161. doi:10.1161/​01.STR.28.11.2155. Retrieved 22 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); zero width space character in |doi= at position 9 (help)
  57. ^ Prcic, Alden (2013). "Sickness Impact Profile (SIP) Score, a Good Alternative Instrument for Measuring Quality of Life in Patients with Ileal Urinary Diversions". Acta Informatica Medica. 21 (3): 160–165. doi:10.5455/aim.2013.21.160-165. Retrieved 22 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  58. ^ Hulsebos, R.G. (1991). "Measuring quality of life with the sickness impact profile: A pilot study". Intensive Care Medicine. 17 (5): 285–288. doi:10.1007/BF01713939. Retrieved 22 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  59. ^ Horsman, John (2003). "The Health Utilities Index (HUI®): concepts, measurement properties and applications". Health And Quality Of Life Outcomes. 1 (54). doi:10.1186/1477-7525-1-54. Retrieved 22 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
  60. ^ Furlong, W.J. (2001). "The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies". Annals of medicine. 33 (5): 375–384. Retrieved 22 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  61. ^ Davis, Erin M. (2013). "Responsiveness of Health State Utility Values in Knee Osteoarthritis". The Journal of Rheumatology. 40 (11). doi:10.3899/jrheum.130176. Retrieved 22 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  62. ^ Harvie, Heidi S. (2013). "Validity of utility measures for women with urge, stress, and mixed urinary incontinence". American Journal of Obstetrics and Gynecology. doi:10.1016/j.ajog.2013.09.025. Retrieved 22 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  63. ^ Ebrahim, Shanil (2013). "Comparison of utility scores from the Visual Analog Scale and Health Utilities Index 3 in children following pediatric intensive care unit admission". Journal of Child Health Care. doi:10.1177/1367493513496909. Retrieved 22 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  64. ^ Meads, D.M. (2009). "The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS)". Multiple Sclerosis. 15 (10): 1228–1238. doi:10.1177/1352458509106714. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  65. ^ Elbers, Roy G. (2012). "Self-report fatigue questionnaires in multiple sclerosis, Parkinson's disease and stroke: a systematic review of measurement properties". Quality of Life Research. 21 (6): 925–944. doi:10.1007/s11136-011-0009-2. Retrieved 20 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  66. ^ "Measures Database". Galen-Research.com. Galen Research. Retrieved 20 November 2013.
  67. ^ Doward, L.C. (2003). "PIN41 DEVELOPMENT OF THE HERPES OUTBREAK IMPACT QUESTIONNAIRE (HOIQ)". Value in Health. 6 (6): 760–761. doi:10.1016/S1098-3015(10)61938-9. Retrieved 19 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  68. ^ Meads, David M. (2009). "Further Validation and Responsiveness Assessment of the Herpes Outbreak Impact Questionnaire and Herpes Symptom Checklist". Value in Health. 12 (2): 397–400. doi:10.1111/j.1524-4733.2008.00450.x. Retrieved 19 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  69. ^ Doward, Lynda C. (2008). "The Development of the Herpes Symptom Checklist and the Herpes Outbreak Impact Questionnaire". Value in Health. 12 (1): 139–145. doi:10.1111/j.1524-4733.2008.00424.x. Retrieved 19 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  70. ^ Twiss, J. "Patient and clinician perceived benefit of early consumption of famciclovir for the treatment of herpes outbreaks famciclovir for the treatment of herpes outbreaks" (PDF). Galen-Research.com. Galen Research. Retrieved 19 November 2013.
  71. ^ Doward, L.C. (1998). "The international development of the RGHQoL: a quality of life measure for recurrent genital herpes". Quality of Life Research. 7 (2): 143–153. doi:10.1023/A:1008857426633. Retrieved 19 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  72. ^ Bartlett, Brenda L. (2008). "Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: The RELIEF trial". Journal of Clinical Virology. 43 (2): 190–195. doi:10.1016/j.jcv.2008.06.004. Retrieved 19 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  73. ^ Patel, R. (1999). "Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection". Sexually Transmitted Infections. 75 (6): 398–402. Retrieved 19 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  74. ^ Leplege, Spencer B. (1999). "Recurrent genital herpes and quality of life in France". Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 8 (4): 365–371. Retrieved 19 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  75. ^ Patel, R. (2001). "Patients' perspectives on the burden of recurrent genital herpes". International journal of STD & AIDS. 12 (10): 640–645. Retrieved 19 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  76. ^ a b Wirén, L.; Whalley, D; McKenna, S; Wilhelmsen, L (2000). "Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: Validation of the measure by Rasch analysis". Clinical Endocrinology. 52 (2): 143–52. doi:10.1046/j.1365-2265.2000.00899.x. PMID 10671940.
  77. ^ Moock, Joern; Friedrich, Nele; Völzke, Henry; Spielhagen, Christin; Nauck, Matthias; Koltowska-Häggström, Maria; Buchfelder, Michael; Wallaschofski, Henri; Kohlmann, Thomas (2011). "Prediction of improvement in quality of life (QoL-AGHDA) in adults with growth hormone deficiency by normative reference limits: Data of the German KIMS cohort". Growth Hormone & IGF Research. 21 (5): 272–8. doi:10.1016/j.ghir.2011.07.005. PMID 21865066.
  78. ^ Gilet, Hélène; Chachuat, Anne; Viala-Danten, Muriel; Auzière, Sébastien; Koltowska-Häggström, Maria (2010). "Application of the Disease-Specific Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) Questionnaire in a General Population: Results from a French Panel Study". Value in Health. 13 (4): 495–500. doi:10.1111/j.1524-4733.2009.00689.x. PMID 20102556.
  79. ^ Badia, X.; Lucas, A.; Sanmartí, A.; Roset, M.; Ulied, A. (1998). "One-year follow-up of quality of life in adults with untreated growth hormone deficiency". Clinical Endocrinology. 49 (6): 765–71. doi:10.1046/j.1365-2265.1998.00634.x. PMID 10209564.
  80. ^ Mukherjee, A.; Tolhurst-Cleaver, S; Ryder, WD; Smethurst, L; Shalet, SM (2004). "The Characteristics of Quality of Life Impairment in Adult Growth Hormone (GH)-Deficient Survivors of Cancer and Their Response to GH Replacement Therapy". Journal of Clinical Endocrinology & Metabolism. 90 (3): 1542–9. doi:10.1210/jc.2004-0832. PMID 15613427.
  81. ^ Gutiérrez, Lia P.; Kołtowska-Häggström, Maria; Jönsson, Peter J.; Mattsson, Anders F.; Svensson, Dag; Westberg, Björn; Luger, Anton (2008). "Registries as a tool in evidence-based medicine: Example of KIMS (Pfizer International Metabolic Database)". Pharmacoepidemiology and Drug Safety. 17 (1): 90–102. doi:10.1002/pds.1510. PMID 17957812.
  82. ^ Patrick, Donald L. (07/2000). "Further Development and Testing of the Migraine-Specific Quality of Life (MSQOL) Measure". Headache: The Journal of Head and Face Pain. 40 (7): 550–560. doi:10.1046/j.1526-4610.2000.00086.x. Retrieved 8 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  83. ^ Garcia-Monco, JC (08/2007). "Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients". Cephalalgia. 27 (8): 920–928. doi:10.1111/j.1468-2982.2007.01367.x. Retrieved 8 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  84. ^ Spigt, Mark (2011). "A randomized trial on the effects of regular water intake in patients with recurrent headaches". Family Practice: 1–6. doi:10.1093/fampra/cmr112. Retrieved 8 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  85. ^ Merelle, SYM (02/2008). "Migraine patients as trainers of their fellow patients in non-pharmacological preventive attack management: short-term effects of a randomized controlled trial". Cephalalgia. 28 (2): 127–138. doi:10.1111/j.1468-2982.2007.01472.x. Retrieved 8 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  86. ^ Doward, L.C. (2009). "The development of patient-reported outcome indices for multiple sclerosis (PRIMUS)". Multiple Sclerosis. 15 (9): 1092–1102. doi:10.1177/1352458509106513. Retrieved 8 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  87. ^ Ziemssen, T. (10/2012). "Study design and first interim results of a registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in Germany (PANGAEA)". Multiple Sclerosis. 18 (4): 222. doi:10.1177/1352458512459019. Retrieved 9 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  88. ^ T., van Lokven (20/10/2011). "Study design of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients (PANGAEA)". 5th Joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. Amsterdam, The Netherlands. Retrieved 09/10/2013. {{cite conference}}: Check date values in: |accessdate= and |date= (help); Unknown parameter |booktitle= ignored (|book-title= suggested) (help); Unknown parameter |coauthors= ignored (|author= suggested) (help); line feed character in |booktitle= at position 69 (help)
  89. ^ Cascione, Mark (12/02/2013). "Patient-Reported Treatment Satisfaction, Reasons for Therapy Change, and Health-Related Quality of Life at Baseline from the Trial To Evaluate Patient OutComes, Safety and Tolerability of Fingolimod". Neurology. 80 (1). Retrieved 9 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  90. ^ Maurer, M (15/10/2012). "Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients". Multiple Sclerosis. 19 (5): 631–638. doi:10.1177/1352458512463481. Retrieved 9 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  91. ^ Keenan, Anne-Maree (2008). "Development and validation of a needs-based quality of life instrument for osteoarthritis". Arthritis Care & Research. 59 (6): 841–848. doi:10.1002/art.23714. Retrieved 20 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  92. ^ "Treating painful hand osteoarthritis using low dose oral prednisolone- assessing short-term pain and imaging outcomes". EU Clinical Trials Register. European Medicines Agency. Retrieved 20 November 2013.
  93. ^ "An open label study to assess the effectiveness of oral methotrexate in reducing pain in knee osteoarthritis". EU Clinical Trials Register. European Medicines Agency. Retrieved 20 November 2013.
  94. ^ "HERO:Hydroxychloroquine Effectiveness in Reducing Symptoms of hand OA, a randomised, double-blind, placebo-controlled trial". Eu Clinical Trials Register. European Medicines Council. Retrieved 20 November 2013.
  95. ^ a b de Jong, Z. (1997). "The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument". Rheumatology. 36 (8): 878–883. doi:10.1093/rheumatology/36.8.878. Retrieved 30 September 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  96. ^ Adams, Jo (2013). "Literacy levels required to complete routinely used patient-reported outcome measures in rheumatology". Rheumatology. 52 (3): 460–464. doi:10.1093/rheumatology/kes296. Retrieved 30 September 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  97. ^ Dougados, Maxime (2013). "Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)". Annals of Rheumatic Disease. 72 (1): 43–50. doi:10.1136/annrheumdis-2011-201282. Retrieved 2 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  98. ^ "Efficacy of tocilizumab in patients with rheumatoid arthritis". Current Controlled Trials. Springer Science+Business Media. Retrieved 2 October 2013.
  99. ^ Quinn, Mark A. (07/01/2005). "Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial". Arthritis & Rheumatism. 52 (1): 27–35. doi:10.1002/art.20712. Retrieved 2 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  100. ^ Bejarano, Victoria (2010). "Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis". Rheumatology. 49 (10): 1971–1974. doi:10.1093/rheumatology/keq194. Retrieved 2 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  101. ^ McKenna, Stephen P. (21/08/2008). "Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses" (PDF). Health and Quality of Life Outcomes. 6 (65): 1–8. doi:10.1186/1477-7525-6-65. Retrieved 2 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
  102. ^ McKenna, S.P. (2006). "The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A measure of health-related quality of life and quality of life for patients with pulmonary hypertension" (PDF). Quality of Life Research. 15: 103–115. doi:10.1007/s11136-005-3513-4. Retrieved 2 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  103. ^ "Measures Database". Galen-Research.com. Galen Research. Retrieved 2 October 2013.
  104. ^ Channick, Richard N. (24/01/2012). "Inhaled treprostinil: a therapeutic review". Drug Design, Development and Therapy. 6: 19–28. doi:10.2147/DDDT.S19281. Retrieved 2 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
  105. ^ Chen, Hubert (2013). "Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension". Health And Quality Of Life Outcomes. 11 (31): 1–8. doi:10.1186/1477-7525-11-31. Retrieved 2 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
  106. ^ Tay, Edgar L.W. (16/06/2011). "Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy". International Journal of Cardiology. 149 (3): 372–376. doi:10.1016/j.ijcard.2010.02.020. Retrieved 2 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  107. ^ Suntharalingam, Jay (2008). "Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension". CHEST. 134 (2): 229–236. doi:10.1378/chest.07-2681. Retrieved 2 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  108. ^ McKenna, S.P. (2005). "Development of the US PSORIQoL: a psoriasis-specific measure of quality of life". International Journal of Dermatology. 44 (6): 462–469. doi:10.1111/j.1365-4632.2005.01941.x. Retrieved 13 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  109. ^ McKenna, S.P. (2003). "Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials". British Journal of Dermatology. 149 (2): 323–331. doi:10.1046/j.1365-2133.2003.05492.x. Retrieved 13 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  110. ^ "Measures Database". Galen-Research.com. Galen Research. Retrieved 13 November 2013.
  111. ^ "Psoriasis: management of psoriasis" (PDF). NICE.org.uk. National Institute for Health and Care Excellence. Retrieved 13 November 2013.
  112. ^ "CAEB071C2201". ClinicalTrialsRegister.eu. EU Clinical Trials Register. Retrieved 13 November 2013.
  113. ^ Brodszky, V (08/2010). "Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey". Scandinavian Journal of Rheumatology. 39 (4): 303–309. doi:10.3109/03009740903468982. PMID 20166848. Retrieved 9 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  114. ^ McKenna, S (02/2004). "Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis". Annals of Rheumatic Diseases. 63 (2): 162–169. doi:10.1136/ard.2003.006296. PMC 1754880. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  115. ^ Marzo-Ortega, Helena (2007). "Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis". Annals of Rheumatic Diseases. 66 (6): 778–781. doi:10.1136/ard.2006.063818. Retrieved 9 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  116. ^ "A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)". ClinicalTrials.gov. Abbott. Retrieved 9 October 2013.
  117. ^ Brown, BC (2010). "The patient-reported impact of scars measure: development and validation". Plastic And Reconstructive Surgery. 125 (5): 1439–1449. doi:10.1097/PRS.0b013e3181d4fd89. Retrieved 13 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  118. ^ Wilburn, J (2009). "PSS36 DEVELOPMENT AND VALIDATION OF THE PATIENT-REPORTED IMPACT OF SCARS MEASURE (PRISM)". Value in Health. 12 (7): A459. doi:10.1016/S1098-3015(10)75273-6. Retrieved 13 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  119. ^ Doward, L.C. (2009). "The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus". Annals of Rheumatic Disease. 68: 196–200. doi:10.1136/ard.2007.086009. Retrieved 20 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  120. ^ Castelino, Madhura (2013). "Comparison of the psychometric properties of health-related quality of life measures used in adults with systemic lupus erythematosus: a review of the literature". Rheumatology. 52 (4): 684–969. doi:10.1093/rheumatology/kes370. Retrieved 20 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  121. ^ Yazdany, Jinoos (2011). "Health-related quality of life measurement in adult systemic lupus erythematosus: Lupus Quality of Life (LupusQoL), Systemic Lupus Erythematosus-Specific Quality of Life Questionnaire (SLEQOL), and Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL)". Measures of Health Status and Quality of Life. 63 (S11): S413–S419. doi:10.1002/acr.20636. Retrieved 20 November 2013. {{cite journal}}: Unknown parameter |month= ignored (help)
Retrieved from "https://en.wikipedia.org/w/index.php?title=List_of_patient-reported_quality_of_life_surveys&oldid=582830507"